The spray drying of unfractionated heparin: Optimization of the operating parameters

Drug Development and Industrial Pharmacy

Volumn 34, Issue 6, 2008, Pages 559-568

  Shur, Jagdeep ^a   Nevell, Thomas G ^a   Shute, Janis K ^a   Smith, James R ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Cystic fibrosis; Dry powder inhaler; Factorial experimental design; Pulmonary drug delivery; Spray drying; Unfractionated heparin

Indexed keywords

HEPARIN;

AIR TEMPERATURE; ARTICLE; DRUG DELIVERY SYSTEM; DRY POWDER; FACTORIAL DESIGN; FLOW RATE; NEBULIZATION; PARAMETER; PARTICLE SIZE; SPRAY DRYING;

ADMINISTRATION, INHALATION; AEROSOLS; CALORIMETRY, DIFFERENTIAL SCANNING; CYSTIC FIBROSIS; HEPARIN; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS;

EID: 45849088060     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701657552     Document Type: Article

References (45)

1. Balfour-Lynn, I. M., Klein, N. J., & Dinwiddie, R. (1997). Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch. Dis. Child., 77, 124-130.
2. Bedrossian, C. W. M., Greenberg, S. D., Singer, D. B., Hansen, J. J., & Rosenberg, H. S. (1976). The lung in cystic fibrosis. Hum. Pathol., 7, 195-204.
3. Bendstrup, K. E., Chambers, C. B., Jensen, J. I., & Newhouse, M. T. (1999a). Lung deposition and clearance of inhaled 99mTc-heparin in healthy volunteers. Am. J. Respir. Crit. Care Med., 160, 1653-1658.
4. Bendstrup, K. E., Gram, J., & Jensen, J. I. (2002). Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur. Respir. J., 19, 606-610.
5. Bendstrup, K. E., Newhouse, M. T., Pedersen, O. F., & Jensen, J. I. (1999b). Characterisation of heparin aerosols generated in jet and ultrasonic nebulisers. J. Aerosol Med., 12, 17-25.
6. Blouquit, S., Regnier, A., Dannhoffer, L., Fermanian, C., Naline, E., Boucher, R., & Chinet, T. (2006). Ion and fluid transport properties of small airways in cystic fibrosis. Am. J. Respir. Crit. Care Med., 174, 299-305
7. Boucher, R. C. (2004). New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J., 23, 146-158.
8. Broadhead, J., Rouan, S. K. E., & Rhodes, C. T. (1992). The spray drying of pharmaceuticals. Drug Dev. Ind. Pharm., 18, 1169-1206.
9. Broughton-Head, V. J., Carroll, M. P., & Shute, J. K. (2005). Unfractionated heparin reduces the elasticity and yield stress of CF sputum. J. Cyst. Fibros., 4(S1), A102.
10. Broughton-Head, V. J., Smith, J. R., Shur, J., & Shute, J. K. (2006). Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm. Pharmacol. Ther., doi:10.1016/j.pupt.2006.08. 008.
11. Byron, P. R., & Patton, J. S. (1994). Drug delivery via the respiratory tract. J. Aerosol Med. Deposition Clear. Eff. Lung, 7, 49-75.
12. Coleman, D. E., & Montgomery, D. C. (1993). A systematic approach to planning for a designed industrial experiment. Technometrics, 35, 1-12.
13. Davis, P. B., Drumm, M., & Konstan, M. W. (1996). Cystic fibrosis. Am. J. Respir. Crit. Care Med., 154, 1229-1256.
14. de Amorim, F. V., Bof, C., Franco, M. B., da Silva, J. B. B., & Nascentes, C. C. (2006). Comparative study of conventional and multivariate methods for aluminium determination in soft drinks by graphite furnace atomic absorption spectroscopy. Microchem. J., 82, 168-173.
15. Derringer, G., & Suich, R. (1980). Simultaneous optimization of several response variables. J. Qual. Technol., 12, 214-219.
16. Fernández, C., Hattan, C. M., & Kerns, R. J. (2006). Semi-synthetic heparin derivatives: Chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups. Carbohydr. Res., 341, 1253-1265.
17. Frijlink, H. W., & de Boer, A. H. (2004). Dry powder inhalers for pulmonary drug delivery. Exp. Opin. Drug Deliv., 1, 67-86.
18. Garrido-López, A., & Tena, M. T. (2005). Experimental design approach for the optimisation of pressurised fluid extraction of additives from polyethylene films. J. Chromatogr. A., 1099, 75-83.
19. Geller, D. E. (2005). Comparing clinical features of the nebuliser, metereddose inhaler, and dry powder inhaler. Respir. Care, 50, 1313-1321.
20. Gordon, M., & Taylor, J. S. (1952). Ideal co-polymers and the second-order transitions of synthetic rubbers. 1. Non-crystalline co-polymers. J. Appl. Chem., 2, 493-500.
21. Haaland, P. D. (1989). Experimental design in biotechnology. New York: Marcel Dekker.
22. Hancock, B. C., & Zografi, G. (1994). The relationship between the glass-transition temperature and the water-content of amorphous pharmaceutical solids. Pharm. Res., 11, 471-477.
23. Heyder, J. (2004). Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac. Soc., 1, 315-320.
24. Heyder, J., Laube, B. L., Jashnani, R., Dalby, R. N., & Zeitlin, P. L. (2000). Targeting aerosol deposition in patients with cystic fibrosis. Effects of alterations in particle size and inspiratory flow rate. Chest, 118, 1069-1076.
25. King, M., & Rubin, B. K. (2002). Pharmacological approaches to discovery and development of new mucolytic agents. Adv. Drug Deliv. Rev., 54, 1475-1490.
26. Kitson, C., Angel, B., Judd, D., Rothery, S., Severs, N. J., Dewar, A., Huang, L., Wadsworth, S. C., Cheng, S. H., Geddes, D. M., & Alton, E. W. F. W. (1999). The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther., 6, 534-546.
27. Le Brun, P. P., de Boer, A. H., Heijerman, H. G., & Frijlink, H. W. (2000). A review of the technical aspects of drug nebulisation. Pharm. World Sci., 22, 75-81.
28. Ledson, M., Gallagher, M., Hart, C. A., & Walshaw, M. (2001). Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur. Respir. J., 17, 36-38.
29. Lethem, M. I., James, S. L., Marriott, C., & Burke, J. F. (1990). The origin of DNA associated with mucus glycoproteins in cystic-fibrosis sputum. Eur. Respir. J., 3, 19-23.
30. Lewis, G. A., Mathieu, D., & Phan-Tan-Luu, R. (1999). Pharmaceutical experimental design. New York: Marcel Dekker.
31. Linsdell, P. (2006). Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp. Physiol., 91, 123-129.
32. Martonen, T., Katz, I., & Cress, W. (1995). Aerosol deposition as a function of airway disease - cystic-fibrosis. Pharm. Res., 12, 96-102.
33. Masters, K. (1985). Spray drying handbook (4th ed.). New York: Longman Scientific & Technical and John Wiley and Sons.
34. Millqvist-Fureby, A., Elofsson, U., & Bergenstahl, B. (2001). Surface composition of spray-dried milk protein-stabilised emulsions in relation to pre-heat treatment of proteins. Colloids Surf. B: Biointerfaces, 21, 47-58.
35. Montgomery, D. C. (1997). Design and analysis of experiments (4th ed.). New York: John Wiley and Sons.
36. Perez-Vilar, J., & Boucher, R. C. (2004). Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease. Free Radic. Biol. Med., 37, 1564-1577.
37. Rezzoug, S. A., & Capart, R. (2003). Assessment of wood liquefaction in acidified ethylene glycol using experimental design methodology. Energy Convers. Manage., 44, 781-792.
38. Riordan, J. R. (2005). Assembly of functional CFTR chloride channels. Annu. Rev. Physiol., 67, 701-718.
39. Roos, Y. H. (1993). Melting and glass transitions of low molecular weight carbohydrates. Carbohydr. Res., 238, 39-48.
40. Sanders, N. N., De Smedt, S. C., & Demeester, J. (2000). The physical properties of biogels and their permeability for macromolecular drugs and colloidal drug carriers. J. Pharm. Sci., 89, 835-849.
41. Serisier, D. J., Shute, J. K., Hockey, P. M., Higgins, B., Conway, J., & Carroll, M. P. (2006). Inhaled heparin in cystic fibrosis. Eur. Respir. J., 27, 354-358.
42. Simha, R., & Boyer, R. F. (1962). On a general relation involving the glass temperature and coefficients of expansion of polymers. J. Chem. Phys., 37, 1003-1007.
43. Taguchi, G. (1987). System of experimental design. New York: Unipub.
44. Tyrrell, D. J., Horne, A. P., Holme, K. R., Preuss, J. M., & Page, C. P. (1999). Heparin in inflammation: Potential therapeutic applications beyond anticoagulation. Adv. Pharmacol., 46, 151-208.
45. Vasconcellos, C., Drazen, J., Janmey, P. A., Wohl, M. E., Lind, S. E., & Stossel, T. P. (1993). Gelsolin reduces the viscosity of cystic-fibrosis sputum in vitro. Clin. Res., 41, A283.